Overall survival in advanced epidermal growth factor receptor mutated non-small cell lung cancer using different tyrosine kinase inhibitors in The Netherlands: a retrospective, nationwide registry studyResearch in context

Overall survival in advanced epidermal growth factor receptor mutated non-small cell lung cancer using different tyrosine kinase inhibitors in The Netherlands: a retrospective, nationwide registry studyResearch in context

Summary: Background: Clinical guidelines advise osimertinib as preferred first line treatment for advanced epidermal growth factor receptor (EGFR) mutated non-small cell lung cancer (NSCLC) with deletions in exon 19 (del19) or exon 21 L858R mutation. However, for first-line osimertinib the real worl...

Full description

Saved in:
Bibliographic Details
Main Authors: Rolof G.P. Gijtenbeek (Author), Ronald A.M. Damhuis (Author), Anthonie J. van der Wekken (Author), Lizza E.L. Hendriks (Author), Harry J.M. Groen (Author), Wouter H. van Geffen (Author)
Format: Book
Published: Elsevier, 2023-04-01T00:00:00Z.
Subjects:
article
Online Access:Connect to this object online.
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

Connect to this object online.

3rd Floor Main Library

Holdings details from 3rd Floor Main Library
Call Number: A1234.567
Copy 1 Available

Similar Items